A Randomized, Contralateral Study To Evaluate Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered 0.6% ISV-403 Three Times Daily For Five Days.

Trial Profile

A Randomized, Contralateral Study To Evaluate Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered 0.6% ISV-403 Three Times Daily For Five Days.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2013

At a glance

  • Drugs Besifloxacin (Primary)
  • Indications Bacterial infections; Conjunctivitis; Ophthalmic infections
  • Focus Pharmacodynamics
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 13 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top